The law firm of Wohl & Fruchter LLP is investigating possible violations
of federal securities laws by officers and directors of Atossa Genetics,
Inc. (Atossa) (NASDAQ: ATOS).
On October 4, 2013, Atossa announced a voluntary recall to remove its
ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology
Test (MASCT) device from the market. The recall was initiated to address
concerns raised by the U.S. Food and Drug Administration (FDA) in a
warning letter received by Atossa in February 2013 about (1) the current
instructions for use (IFU); (2) certain promotional claims used to
market these devices; and (3) the need for FDA clearance for certain
changes made to the Nipple Aspirate Fluid (NAF) specimen collection
process identified in the current IFU.
Upon the above news, ATOS shares have declined over 45% in trading on
October 7, 2013.
Persons with relevant information, and ATOS shareholders with questions
about this investigation, are invited to contact the attorney below, or
our Firm by calling 866.833.6245.
Additional information is available on our website at: http://www.wohlfruchter.com/cases/atos.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation arising from
fraud and other fiduciary breaches by corporate managers, as well as
other complex litigation matters. Please visit our website, www.wohlfruchter.com,
to learn more about our Firm, or contact one of our partners.
This release may be deemed to constitute attorney advertising.
Copyright Business Wire 2013